Rosacea

What is it?

Rosacea is a chronic inflammatory dermatological condition characterized by persistent centrofacial erythema (redness concentrated in the central area of the face). The disorder primarily manifests as facial redness, papules (small raised bumps), pustules (pus-filled lesions), and telangiectasia (visible small blood vessels), predominantly affecting the cheeks, nose, chin, and forehead. Unlike acne vulgaris, rosacea does not present with comedones (blackheads or whiteheads) and typically develops in adulthood.

Who is affected?

Rosacea affects approximately 1 in 20 individuals (5.46% global prevalence), making it a relatively common dermatological condition. The disorder demonstrates specific demographic patterns:

• Age demographics: Peak onset occurs between 30-50 years of age
• Gender distribution: Equal prevalence in males and females, though phymatous changes (skin thickening) occur more frequently in men
• Ethnic predisposition: Higher prevalence in individuals of Northern European descent, particularly those with fair skin phototypes
• Genetic factors: Familial clustering observed in approximately 30% of cases, suggesting hereditary predisposition

What causes it?

The etiology of rosacea involves multiple interconnected pathogenic mechanisms:

• Primary pathogenic mechanisms: Dysregulation of the innate immune system, neurovascular dysfunction, and altered cutaneous microbiome composition
• Contributing factors: Genetic predisposition, chronic ultraviolet exposure, and environmental influences
• Triggering elements: Heat exposure, spicy foods, alcoholic beverages (particularly red wine), emotional stress, physical exertion, and certain cosmetic products
• Microbial factors: Increased density of Demodex folliculorum mites and potential bacterial involvement, though rosacea is not considered contagious

What are the clinical features?

Rosacea presents with variable clinical features that can be categorized into objective signs and subjective symptoms:

Signs (objective, observable findings):

• Persistent centrofacial erythema (facial redness that does not resolve)
• Inflammatory papulopustular lesions (red bumps with or without pus, distinct from acne)
• Telangiectasia (dilated superficial blood vessels creating visible red lines)
• Flushing episodes (transient redness triggered by specific stimuli)
• Facial edema (swelling, particularly around the eyes and cheeks)
• Phymatous changes (skin thickening and enlargement, most commonly affecting the nose)
• Ocular signs (conjunctival redness, lid margin inflammation, visible blood vessels in eyes)

Symptoms (subjective, patient-reported experiences):

• Burning sensations (feeling of heat or warmth in affected areas)
• Stinging sensations (sharp, prickling discomfort)
• Facial tenderness (sensitivity to touch in affected areas)
• Ocular symptoms (eye dryness, grittiness, irritation, foreign body sensation)
• Pruritus (itching, though less common than burning/stinging)

Disease progression:

Rosacea typically follows a chronic relapsing-remitting course with periods of exacerbation alternating with relative quiescence.

How is it diagnosed?

Diagnosis of rosacea is primarily clinical, based on characteristic morphological features:

• Clinical assessment methods: Visual examination focusing on the distribution and morphology of lesions, assessment of triggering factors, and evaluation for ocular involvement
• Diagnostic criteria: Based on the 2017 National Rosacea Society consensus, requiring either persistent centrofacial erythema or phymatous changes for diagnosis
• Differential considerations: Distinction from acne vulgaris (absence of comedones), seborrheic dermatitis (different distribution pattern), systemic lupus erythematosus (serological differences), and photodermatitis (exposure patterns)

What treatment options are available?

Therapeutic management of rosacea employs a multimodal approach:

• First-line therapeutic approaches:

  • Topical anti-inflammatory agents (metronidazole, ivermectin, azelaic acid)
  • Topical vasoconstrictors for persistent erythema (brimonidine, oxymetazoline)
  • Systemic tetracyclines for moderate to severe papulopustular disease

• Alternative treatment modalities:

  • Laser and light-based therapies for vascular components
  • Low-dose isotretinoin for refractory cases
  • Surgical intervention for advanced phymatous changes

• Lifestyle modifications and self-care:

  • Identification and avoidance of personal triggering factors
  • Daily broad-spectrum photoprotection (minimum SPF 30)
  • Gentle skincare regimen with pH-balanced cleansers

Key points for patients

• Rosacea is a chronic condition requiring long-term management rather than cure
• Early intervention can prevent disease progression and minimize cosmetic impact
• Treatment typically involves combination therapy tailored to individual phenotype
• Maintenance therapy is usually necessary to prevent relapse
• Professional consultation is recommended for persistent facial erythema or inflammatory lesions
• Ocular symptoms warrant ophthalmological evaluation to prevent complications